- $181.77m
- $180.24m
- $236.74m
- 59
- 51
- 37
- 47
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 152 | 169 | 192 | 216 | 237 |
Cost of Revenue | |||||
Gross Profit | 91.7 | 105 | 118 | 138 | 147 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 171 | 172 | 194 | 222 | 241 |
Operating Profit | -19.7 | -2.77 | -1.93 | -5.76 | -4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -18.9 | -2.36 | -1.75 | -5.42 | -2.81 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.8 | -2.44 | -1.75 | -3.65 | -0.835 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.8 | -2.44 | -1.75 | -3.65 | -0.835 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.8 | -2.44 | -1.75 | -3.65 | -0.835 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.779 | -0.109 | -0.075 | -0.109 | -0.015 |